Amneal Pharmaceuticals announces unaudited preliminary Q2 revenue between $720M and $730M

1 day ago 1

Amneal Pharmaceuticals (NASDAQ:AMRX) announced on Monday unaudited preliminary Q2 revenue of $720 million to $730 million, versus consensus revenue estimates of $748.18M, an increase of approximately 3% versus the same period in 2024.
Shares of AMRX jumped nearly 7% during

Recommended For You